Biomarker testing for people with advanced lung cancer in England
File(s)
Author(s)
Type
Journal Article
Abstract
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. Methods: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. Results: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. Conclusions: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.
Date Issued
2021-06-01
Online Publication Date
2021-11-24T14:37:02Z
Date Acceptance
2021-04-06
ISSN
2666-3643
Publisher
Elsevier
Journal / Book Title
JTO Clinical and Research Reports
Volume
2
Issue
6
Copyright Statement
© 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/34590024
S2666-3643(21)00035-7
Subjects
Biomarkers
Mutation testing
Non–small cell lung cancer
Personalized medicine
Targeted therapy
Biomarkers
Mutation testing
Non–small cell lung cancer
Personalized medicine
Targeted therapy
Publication Status
Published
Country
United States
Article Number
ARTN 100176
Date Publish Online
2021-04-27